Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash declines year over year
Q1 FY2026 net change in cash of $5.75M (cash outflow) fell 40.3% year over year, ahead of the -46.3% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -38.9% a year.
Context
- Net change in cash grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -40.3% holds above the trailing-twelve-month pace of -46.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (13.33M) USD
- Year-over-year change
- -0.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.33M) | -0.5% |
| FY2024 | 2024-12-31 | (13.27M) | +72.9% |
| FY2023 | 2023-12-31 | (49.01M) | +16.1% |
| FY2022 | 2022-12-31 | (58.39M) | -143.0% |
| FY2021 | 2021-12-31 | 135.73M | — |
Net Change in Cash vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -46.3% is the 6th highest of 9, against a peer median of +61.5%.
- Over three fiscal years its annual growth of -38.9% compares with a peer median of -58.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $39.89M USD | +45.4% | -38.2% | 62323.4% | |
| LTM Mar 2026 | $32.55M USD | -179.4% | — | 32.7% | |
| LTM Mar 2026 | $29.52M USD | +295.4% | -58.6% | 2952.1% | |
| LTM Mar 2026 | €22.84M EUR | -203.0% | -73.8% | 77884.9% | |
| LTM Mar 2026 | $22.28M USD | +158.7% | -14.5% | 49.4% | |
| LTM Mar 2026 | $21.06M USD | +126.4% | — | — | |
| LTM Mar 2026 | $11.67M USD | +77.5% | -84.4% | — | |
| LTM Mar 2026 | $10M USD | -331.8% | — | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $9.45M USD | -46.3% | -38.9% | — |
| Peer median (excluding ARTV) | — | +61.5% | -58.6% | 2952.1% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.83M) | (58.79M) | (28.72M) | (65.37M) | (83.87M) |
| Depreciation & Amortization | 248K | 1.16M | 2.27M | 2.43M | 2.6M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.31M | 6.58M | 7.05M | 6.98M | 6.82M |
| Change in Working Capital | 33.41M | (3.87M) | (28.28M) | (325K) | (424K) |
| Accounts Receivables | (468K) | (57K) | (1.23M) | 1.61M | 79K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.24M) | 190K | (408K) | 519K | (760K) |
| Other Working Capital | 35.13M | (4M) | (26.64M) | (2.46M) | 257K |
| Other Non-Cash Items | 18.55M | 4.08M | 251K | 1.26M | (1.88M) |
| Operating Cash Flow | (15.3M) | (50.83M) | (47.43M) | (55.03M) | (76.75M) |
| Capital Expenditures | (1.72M) | (6.3M) | (3.26M) | (642K) | (2.59M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (49.52M) | (176.17M) | (44.88M) |
| Sales of Investments | 0 | 0 | 26.8M | 56.35M | 110.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.72M) | (6.3M) | (25.98M) | (120.46M) | 63.41M |
| Debt Repayment | 0 | 0 | 0 | (149K) | (132K) |
| Common Stock Issued | 0 | 0 | 0 | 166.51M | 371K |
| Common Stock Repurchased | 0 | (5K) | (12K) | (4.18M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.86M) | (1.26M) | 24.4M | 51K | (230K) |
| Financing Cash Flow | 152.75M | (1.26M) | 24.39M | 162.23M | 9K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 135.73M | (58.39M) | (49.01M) | (13.27M) | (13.33M) |
| Free Cash Flow | (17.03M) | (57.13M) | (50.69M) | (55.67M) | (79.34M) |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.